Newly Designed Poxviral Promoters to Improve Immunogenicity and Efficacy of MVA-NP Candidate Vaccines against Lethal Influenza Virus Infection in Mice

Influenza, a respiratory disease mainly caused by influenza A and B, viruses of the Orthomyxoviridae, is still a burden on our society’s health and economic system. Influenza A viruses (IAV) circulate in mammalian and avian populations, causing seasonal outbreaks with high numbers of cases. Due to the high variability in seasonal IAV triggered by antigenic drift, annual vaccination is necessary, highlighting the need for a more broadly protective vaccine against IAV. The safety tested Modified Vaccinia virus Ankara (MVA) is licensed as a third-generation vaccine against smallpox and serves as a potent vector system for the development of new candidate vaccines against different pathogens. Here, we generated and characterized recombinant MVA candidate vaccines that deliver the highly conserved internal nucleoprotein (NP) of IAV under the transcriptional control of five newly designed chimeric poxviral promoters to further increase the immunogenic properties of the recombinant viruses (MVA-NP). Infections of avian cell cultures with the recombinant MVA-NPs demonstrated efficient synthesis of the IAV-NP which was expressed under the control of the five new promoters. Prime-boost or single shot immunizations in C57BL/6 mice readily induced circulating serum antibodies’ binding to recombinant IAV-NP and the robust activation of IAV-NP-specific CD8+ T cell responses. Moreover, the MVA-NP candidate vaccines protected C57BL/6 mice against lethal respiratory infection with mouse-adapted IAV (A/Puerto Rico/8/1934/H1N1). Thus, further studies are warranted to evaluate the immunogenicity and efficacy of these recombinant MVA-NP vaccines in other IAV challenge models in more detail.

[1]  M. Addo,et al.  Stabilized recombinant SARS-CoV-2 spike antigen enhances vaccine immunogenicity and protective capacity , 2022, The Journal of clinical investigation.

[2]  E. Karita,et al.  Monitoring of Adverse Events in Recipients of the 2-Dose Ebola Vaccine Regimen of Ad26.ZEBOV Followed by MVA-BN-Filo in the UMURINZI Ebola Vaccination Campaign , 2022, The Journal of infectious diseases.

[3]  G. Sutter,et al.  Protective CD8+ T Cell Response Induced by Modified Vaccinia Virus Ankara Delivering Ebola Virus Nucleoprotein , 2022, Vaccines.

[4]  B. Bošnjak,et al.  Immunogenicity and efficacy of the COVID-19 candidate vector vaccine MVA-SARS-2-S in preclinical vaccination , 2021, Proceedings of the National Academy of Sciences.

[5]  Robert T. Chen,et al.  The Brighton Collaboration standardized template for collection of key information for risk/benefit assessment of a Modified Vaccinia Ankara (MVA) vaccine platform , 2020, Vaccine.

[6]  S. Hensley,et al.  Challenges of Making Effective Influenza Vaccines. , 2020, Annual review of virology.

[7]  M. Addo,et al.  Safety and immunogenicity of a modified vaccinia virus Ankara vector vaccine candidate for Middle East respiratory syndrome: an open-label, phase 1 trial , 2020, The Lancet Infectious Diseases.

[8]  J. Mascola,et al.  Next-generation influenza vaccines: opportunities and challenges , 2020, Nature Reviews Drug Discovery.

[9]  C. Broder,et al.  A Soluble Version of Nipah Virus Glycoprotein G Delivered by Vaccinia Virus MVA Activates Specific CD8 and CD4 T Cells in Mice , 2019, Viruses.

[10]  C. Mameli,et al.  Influenza Vaccination: Effectiveness, Indications, and Limits in the Pediatric Population , 2019, Front. Pediatr..

[11]  F. Krammer.  The human antibody response to influenza A virus infection and vaccination , 2019, Nature Reviews Immunology.

[12]  L. Loh,et al.  Broad CD8+ T cell cross-recognition of distinct influenza A strains in humans , 2018, Nature Communications.

[13]  G. Sutter,et al.  CD8+ T Cells Responding to the Middle East Respiratory Syndrome Coronavirus Nucleocapsid Protein Delivered by Vaccinia Virus MVA in Mice , 2018, Viruses.

[14]  N. Alharbi.  Poxviral promoters for improving the immunogenicity of MVA delivered vaccines , 2018, Human vaccines & immunotherapeutics.

[15]  G. Sutter,et al.  Distribution and absence of generalized lesions in mice following single dose intramuscular inoculation of the vaccine candidate MVA-MERS-S , 2018, Biologicals.

[16]  R. Webster,et al.  Influenza Virus: Dealing with a Drifting and Shifting Pathogen. , 2018, Viral immunology.

[17]  G. Sutter,et al.  Chapter Five Modified Vaccinia Virus Ankara History, Value in Basic Research, and Current Perspectives for Vaccine Development , 2017, Advances in Virus Research.

[18]  G. Rimmelzwaan,et al.  Protein and modified vaccinia virus Ankara‐based influenza virus nucleoprotein vaccines are differentially immunogenic in BALB/c mice , 2017, Clinical and experimental immunology.

[19]  F. Krammer,et al.  Universal influenza virus vaccines and therapeutic antibodies. , 2017, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[20]  G. Sutter,et al.  Myristoylation increases the CD8+T-cell response to a GFP prototype antigen delivered by modified vaccinia virus Ankara. , 2016, The Journal of general virology.

[21]  Michael B. Doud,et al.  Site-Specific Amino Acid Preferences Are Mostly Conserved in Two Closely Related Protein Homologs , 2015, bioRxiv.

[22]  Anne M Johnson,et al.  Natural T Cell-mediated Protection against Seasonal and Pandemic Influenza. Results of the Flu Watch Cohort Study. , 2015, American journal of respiratory and critical care medicine.

[23]  P. Palese,et al.  Advances in the development of influenza virus vaccines , 2015, Nature Reviews Drug Discovery.

[24]  Rustom Antia,et al.  Initial viral load determines the magnitude of the human CD8 T cell response to yellow fever vaccination , 2015, Proceedings of the National Academy of Sciences.

[25]  K. Broman,et al.  Modified Vaccinia Virus Ankara Encoding Influenza Virus Hemagglutinin Induces Heterosubtypic Immunity in Macaques , 2014, Journal of Virology.

[26]  C. Guzmán,et al.  Gene Expression Driven by a Strong Viral Promoter in MVA Increases Vaccination Efficiency by Enhancing Antibody Responses and Unmasking CD8+ T Cell Epitope , 2014, Vaccines.

[27]  G. Sutter,et al.  Rapid Expansion of CD8+ T Cells in Wild-Type and Type I Interferon Receptor-Deficient Mice Correlates with Protection after Low-Dose Emergency Immunization with Modified Vaccinia Virus Ankara , 2014, Journal of Virology.

[28]  T. Goodpaster,et al.  A Flexible Mouse-On-Mouse Immunohistochemical Staining Technique Adaptable to Biotin-Free Reagents, Immunofluorescence, and Multiple Antibody Staining , 2014, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.

[29]  F. Falkner,et al.  MVA Vectors Expressing Conserved Influenza Proteins Protect Mice against Lethal Challenge with H5N1, H9N2 and H7N1 Viruses , 2014, PloS one.

[30]  B. Moss,et al.  Cascade regulation of vaccinia virus gene expression is modulated by multistage promoters. , 2013, Virology.

[31]  Jonathan J Deeks,et al.  Cellular immune correlates of protection against symptomatic pandemic influenza , 2013, Nature Medicine.

[32]  S. Gilbert.  Clinical development of Modified Vaccinia virus Ankara vaccines. , 2013, Vaccine.

[33]  B. Moss.  Poxvirus DNA replication. , 2013, Cold Spring Harbor perspectives in biology.

[34]  G. Sutter,et al.  Middle East Respiratory Syndrome Coronavirus Spike Protein Delivered by Modified Vaccinia Virus Ankara Efficiently Induces Virus-Neutralizing Antibodies , 2013, Journal of Virology.

[35]  G. Wolf,et al.  Transient elimination of circulating bovine viral diarrhoea virus by colostral antibodies in persistently infected calves: a pitfall for BVDV-eradication programs? , 2012, Veterinary microbiology.

[36]  S. Gilbert,et al.  Expression and Cellular Immunogenicity of a Transgenic Antigen Driven by Endogenous Poxviral Early Promoters at Their Authentic Loci in MVA , 2012, PloS one.

[37]  Tao Dong,et al.  Preliminary Assessment of the Efficacy of a T-Cell–Based Influenza Vaccine, MVA-NP+M1, in Humans , 2012, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[38]  Y. Suezer,et al.  Critical Role of Perforin-dependent CD8+ T Cell Immunity for Rapid Protective Vaccination in a Murine Model for Human Smallpox , 2012, PLoS pathogens.

[39]  M. Eichelberger,et al.  Discordant antigenic drift of neuraminidase and hemagglutinin in H1N1 and H3N2 influenza viruses , 2011, Proceedings of the National Academy of Sciences.

[40]  P. Blair,et al.  Live attenuated influenza vaccine (LAIV) impacts innate and adaptive immune responses. , 2011, Vaccine.

[41]  A. Osterhaus,et al.  Induction of Virus-Specific Cytotoxic T Lymphocytes as a Basis for the Development of Broadly Protective Influenza Vaccines , 2011, Journal of biomedicine & biotechnology.

[42]  T. Randall,et al.  Contributions of Antinucleoprotein IgG to Heterosubtypic Immunity against Influenza Virus , 2011, The Journal of Immunology.

[43]  Ravi S. Misra,et al.  Regulation of Antinucleoprotein IgG by Systemic Vaccination and Its Effect on Influenza Virus Clearance , 2011, Journal of Virology.

[44]  A. Hill,et al.  Potent CD8+ T-Cell Immunogenicity in Humans of a Novel Heterosubtypic Influenza A Vaccine, MVA−NP+M1 , 2011, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[45]  Marc Schweneker,et al.  Immediate-Early Expression of a Recombinant Antigen by Modified Vaccinia Virus Ankara Breaks the Immunodominance of Strong Vector-Specific B8R Antigen in Acute and Memory CD8 T-Cell Responses , 2010, Journal of Virology.

[46]  Zhongde Wang,et al.  Modified H5 promoter improves stability of insert genes while maintaining immunogenicity during extended passage of genetically engineered MVA vaccines , 2009, Vaccine.

[47]  H. Gundersen,et al.  Stereological Estimates of Alveolar Number and Size and Capillary Length and Surface Area in Mice Lungs , 2009, Anatomical record.

[48]  Magdalini Moutaftsi,et al.  Dissociation between Epitope Hierarchy and Immunoprevalence in CD8 Responses to Vaccinia Virus Western Reserve1 , 2008, The Journal of Immunology.

[49]  D. Busch,et al.  Cross-competition of CD8+ T cells shapes the immunodominance hierarchy during boost vaccination , 2007, The Journal of experimental medicine.

[50]  W. Kastenmuller,et al.  Cross-Priming of Cytotoxic T Cells Dictates Antigen Requisites for Modified Vaccinia Virus Ankara Vector Vaccines , 2007, Journal of Virology.

[51]  D. Bruder,et al.  Cellular immunity and lung injury in respiratory virus infection. , 2006, Viral immunology.

[52]  D. Fleming,et al.  The impact of influenza on the health and health care utilisation of elderly people. , 2005, Vaccine.

[53]  D. Tscharke,et al.  Identification of poxvirus CD8+ T cell determinants to enable rational design and characterization of smallpox vaccines , 2005, The Journal of experimental medicine.

[54]  A. Lapedes,et al.  Mapping the Antigenic and Genetic Evolution of Influenza Virus , 2004, Science.

[55]  I. Brown,et al.  Genetic relationships, serological cross-reaction and cross-protection between H1N2 and other influenza A virus subtypes endemic in European pigs. , 2004, Virus research.

[56]  P. Heinen,et al.  Respiratory and systemic humoral and cellular immune responses of pigs to a heterosubtypic influenza A virus infection. , 2001, The Journal of general virology.

[57]  J. Hedreen,et al.  Unbiased stereology? , 1999, Trends in Neurosciences.

[58]  A. Vitiello,et al.  Immunodominance analysis of CTL responses to influenza PR8 virus reveals two new dominant and subdominant Kb-restricted epitopes. , 1996, Journal of immunology.

[59]  B. Moss.  Genetically engineered poxviruses for recombinant gene expression, vaccination, and safety. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[60]  B. Moss,et al.  Nonreplicating vaccinia vector efficiently expresses recombinant genes. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[61]  W. Fitch,et al.  Biological and genetic evolution of the nucleoprotein gene of human influenza A viruses. , 1989, The Journal of general virology.

[62]  A. McMichael,et al.  The epitopes of influenza nucleoprotein recognized by cytotoxic T lymphocytes can be defined with short synthetic peptides , 1986, Cell.

[63]  B. Moss,et al.  Vaccinia virus expression vector: coexpression of beta-galactosidase provides visual screening of recombinant virus plaques , 1985, Molecular and cellular biology.

[64]  E. Weibel,et al.  PRACTICAL STEREOLOGICAL METHODS FOR MORPHOMETRIC CYTOLOGY , 1966, The Journal of cell biology.

[65]  J. Kreijtz,et al.  Easy and efficient protocols for working with recombinant vaccinia virus MVA. , 2012, Methods in molecular biology.

[66]  G. McFadden.  Poxvirus tropism , 2005, Nature Reviews Microbiology.

[67]  Christine Ruehl-Fehlert,et al.  Revised guides for organ sampling and trimming in rats and mice--Part 3. A joint publication of the RITA and NACAD groups. , 2004, Experimental and toxicologic pathology : official journal of the Gesellschaft fur Toxikologische Pathologie.

[68]  Christine Ruehl-Fehlert,et al.  Revised guides for organ sampling and trimming in rats and mice--Part 2. A joint publication of the RITA and NACAD groups. , 2004, Experimental and toxicologic pathology : official journal of the Gesellschaft fur Toxikologische Pathologie.

[69]  Thomas Nolte,et al.  Revised guides for organ sampling and trimming in rats and mice--part 1. , 2003, Experimental and toxicologic pathology : official journal of the Gesellschaft fur Toxikologische Pathologie.

[70]  W Chen,et al.  Dissecting the multifactorial causes of immunodominance in class I-restricted T cell responses to viruses. , 2000, Immunity.